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Abstract
The process by which oligodendrocyte progenitors differentiate into mature oligodendrocytes is
complex and incompletely understood in part because of the paucity of oligodendrocyte precursors
cell lines that can be studied in culture. We have developed a non-immortalized rat oligodendrocyte
precursor line, called OL-1, which behaves in a fashion consistent with developing oligodendrocytes
in vivo. This OL-1 line provides a model for the study of oligodendrocyte development and offers
an alternative to the CG-4 cell line. When OL-1 cells are propagated in conditioned growth media,
they have morphology consistent with immature oligodendrocytes and exhibit A2B5 antigen positive
and myelin basic protein-negative immunoreactivity. Withdrawal of conditioned growth media and
culture in serum-free medium results in OL-1 cell maturation, manifested by a shift to myelin basic
protein-positive immunoreactivity, A2B5 antigen-negative immunoreactivity, decreased NG2
mRNA expression, increased expression of proteolipid protein mRNA, and increased expression of
CNP protein. In addition, the expression of proteolipid protein and its splicing variant DM-20 exhibit
a pattern that is similar to brain proteolipid protein expression during development. When OL-1 cells
are exposed to Insulin-like growth factor-I, there are significant increases in proteolipid protein
mRNA expression ( p < 0.05), the number of cell processes ( p < 0.05), and cell number ( p < 0.05).
Treatment with the caspase inhibitors Z-DEVD-FMK and Z-VAD-FMK (inhibitors of caspases 3,
6, 7, 8, 10 and 1, 3, 4, respectively), Insulin-like growth factor-I, or both, results in a similar increase
in cell number. Because Insulin-like growth factor-I does not substantially increase the BrdU labeling
of OL-1 cells, these data collectively indicate that Insulin-like growth factor-I increases OL-1 cell
number predominately by promoting survival, rather than stimulating proliferation. This non-
immortalized oligodendrocyte precursor cell line, therefore, exhibits behavior consistent with the in
vivo development of oligodendrocytes and provides an excellent model for the study of developing
oligodendrocytes.
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The sequential events occurring during oligodendrocyte lineage development, while well
described both morphologically and by the expression of specific molecular markers, are
complex and incompletely understood. Oligodendrocyte precursor cells are characterized by
the expression of NG2 proteoglycan (NG2) (Nishiyama et al., 1996), A2B5 antigen (A2B5)
(Raff et al., 1983; Rao et al., 1998; Lee et al., 2000), and the platelet-derived growth factor
receptor alpha (PDGFRα) (McKinnon et al., 1990). After exiting the cell cycle,
oligodendrocyte precursor cells develop into pro-oligodendrocytes that are characterized by
an increase in myelinating processes. This is accompanied by decreased expression of NG2,
A2B5, and PDGFRα (Hall et al., 1996) and the onset of O4 antigen expression (O4). As pro-
oligodendrocytes differentiate into mature oligodendrocytes, O4 expression decreases and
galactocerebroside (GalC), 2′,3′-cyclic nucleotide-3′-phosphodiesterase, proteolipid protein
(PLP), and myelin basic protein (MBP) expression increases.
The coordinated expression of several key genes, such as sonic hedgehog, PAX-6, nkx-2.2,
olig-1, olig-2, and sox-10, in CNS likely specifies the development of the oligodendrocyte
lineage. In addition, a number of growth factors appear important. There is evidence that
platelet-derived growth factor (PDGF), fibroblast growth factor-2, (FGF-2), and insulin-like
growth factor-I (IGF-I) influence oligodendrocyte lineage cell proliferation and survival. Both
PDGF and FGF-2 are mitogenic to A2B5 + OPCs (Noble et al., 1988; Raff et al., 1988;
Richardson et al., 1988; Gard and Pfeiffer, 1993; Calver et al., 1998; Fruttiger et al., 1999),
and FGF-2 has been shown to prevent maturation of cultured GalC + pro-oligodendrocytes
into mature oligodendrocytes (Gard and Pfeiffer, 1993). Furthermore, when cultured in the
combination of PDGF and FGF-2, OPCs grow indefinitely in culture without further
differentiation as judged by a lack of O4 expression (Bogler et al., 1990). IGF-I appears to
enhance OPC survival (Barres et al., 1993), but also appears to promote differentiative events
(McMorris and Dubois-Dalcq, 1988). In primary glial cell culture, IGF-I stimulates an increase
in oligodendrocyte number by inhibiting OPC apoptosis (Ye and D’Ercole, 1999), actions that
appear to be mediated through the phosphatidylinositol 3-kinase pathway (Vemuri and
McMorris, 1996). In such cultures, IGF-I also stimulates oligodendrocyte development and
myelination (McMorris et al., 1986; McMorris and Dubois-Dalcq, 1988; Mozell and
McMorris, 1991; Ye and D’Ercole, 1999).
A better understanding of oligodendrocyte development and myelination is central to
developing modalities to treat demyelinating disorders. While in vivo systems provide a more
physiologic model, the existence of multiple neural cell types hinders the characterization of
signaling specifically in oligodendrocyte lineage cells. Pure cultures of oligodendrocytes and
their precursors address this problem. A number of cell culture models of oligodendrocyte
development have been described, including immortalized cell lines (Jung et al., 1995; Richter-
Landsberg and Heinrich, 1996; Verity et al., 1993; Matsushita et al., 2005), primary cell culture
(McCarthy and de Vellis, 1980), and an OPC cell line (Louis et al., 1992). Immortalized cell
lines are less attractive because their behavior has been fundamentally altered by
immortalization. While study of primary cell cultures is appealing, the labor and expense of
preparing them in sufficient quantity for multiple experiments makes them less than optimal.
The study of non-immortalized cells offers an alternative method. We report here a non-
immortalized rat oligodendrocyte precursor line, called OL-1. Like the CG-4 cell line, OL-1
cells behave similar to primary cultured oligodendrocytes. They can be propagated in culture
to generate large numbers of OPCs that can be induced to differentiate into mature
oligodendrocytes. Using OL-1 cells, we show that IGF-I promotes OPC maturation and
increased OPC number, as judged by increases in myelin gene expression, the number of cell
processes, and cell survival. The OL-1 cell line, therefore, provides an alternative non-
immortalized cell culture model for the study of oligodendrocyte development.
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2.1. Generation of the OL-1 oligodendrocyte precursor cell line
2.1.1. Isolation of oligodendrocyte progenitors—Oligodendrocyte precursors were
prepared and isolated from P2 rat brains according to a modified method derived from
McCarthy and de Vellis (1980). P2 rats were sacrificed and brains placed in tissue culture
dishes on ice containing cold Dulbecco’s Modified Essential Media (DMEM), 20 mM Hepes,
and 50 μg/mL gentamycin. Meninges, cerebellum, and olfactory bulbs were discarded.
Remaining tissue was pooled, rinsed with buffer [Hanks Balanced Salt Solution with phenol
red and Ca2+/Mg2+ (Invitrogen, Carlsbad, CA) containing 5.5 mM Cysteine (Sigma–Aldrich,
St. Louis, MO), 2 mM EDTA, 20 mM Hepes], and transferred to a conical tube. Remaining
liquid was aspirated and papain solution with DNAse [10–20 U papain (Sigma–Aldrich, St.
Louis, MO) with 0.25 mg DNAse (Worthington Biochemical, Lakewood, NJ) per mL buffer]
was added and incubated for 1 h with intermittent trituration. After brains were dissociated,
cool DMEM with 0.1% BSA and 50 μg/mL gentamycin was added and cells divided into two
50 mL conical tubes. Cells were filtered through 250, 150, and then 75 mesh conical filters
followed each time by a wash with DMEM/BSA/Gentamycin. Tubes were brought up to 50
mL with DMEM/BSA/Gentamycin and centrifuged at 1000 rpm for 7 min.
Poly-D-lysine (PDL) (Sigma–Aldrich, St. Louis, MO)-coated flat bottom T75 flasks without
a canted neck (BD Biosciences, San Jose, CA) were prepared by adding a 2–10 μg/mL PDL
solution in sterile water for 1–2 h, followed by aspiration, and air drying. Washed cells were
plated at a ratio of one brain per flask in 10% fetal calf serum in DMEM containing high
glucose, 20–25 mM Hepes, pyruvate, 2 mM glutamine, and 10 ug/mL gentamycin), termed
here Complete Medium (CM) and cultured at 37 °C.
Once adequate monolayers formed, flasks were capped tightly and placed on a rotary shaker-
incubator at 180 rpm and 37 °C for 2–3 h. Media containing microglia was removed, replaced
with fresh CM and equilibrated for 2 h at 37 °C. The flasks were placed back on the rotary
shaker-incubator at 220–250 rpm and 37 °C. After shaking overnight, the medium containing
oligodendrocyte progenitors was removed, and cells pelleted at 1000 rpm for 7 min. The pellet
was resuspended in 30 mL of CM, split into 3 × 10 cm Petri dishes (Fisher Scientific, Pittsburgh,
PA), and allowed to settle for 2 h at 37 °C. After settling, the plates were gently agitated to
bring the oligodendrocyte progenitors into suspension, while the microglia remained attached.
The media containing progenitors was removed, pooled, and spun down at 1000 rpm for 7 min
at 4 °C.
This pellet was re-suspended in 10 mL of a solution termed Conditioned Growth Media (CGM;
described below) and 450,000–500,000 cells were plated in each PDL-coated 10 cm tissue
culture dish and cultured at 37 °C. CGM is composed of 30% B104-conditioned media and
70% serum free-defined media (SFM) [25 μg/mL transferrin (Sigma–Aldrich, St. Louis, MO),
30 nM triiodothyronine (Calbiochem, San Diego, CA), 20 nM hydrocortisone (Sigma–Aldrich,
St. Louis, MO), 20 nM progesterone (Sigma–Aldrich, St. Louis, MO), 10 nM biotin
(Invitrogen, Carlsbad, CA), 1× trace elements (Cellgrow, medium B, 1000× stock), 30 nM
selenium (Sigma–Aldrich, St. Louis, MO), 1 μg/mL putrescine (Sigma–Aldrich, St. Louis,
MO), 0.1% BSA (Fraction V; Sigma–Aldrich, St. Louis, MO), 5 U/mL penicillin/
streptomycin), 10 μg/mL insulin]. B104-conditioned media was generated by culturing sub-
confluent B104 neuroblastoma cells with SFM for 2 days. After 2 days, B104-conditioned
media is collected, sterile filtered, and stored frozen at −20 °C.
The cells were expanded in CGM for approximately 4 days. Media was changed every 2 days.
After the cells were grown to sub-confluence, they were passaged (see next section) to a PDL-
coated 24-well dish and serially diluted to an approximate density of 10,000, 5000, 2500, 1250,
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625, and 312 cells per well and expanded in CGM for 4 days. Culture dilutions that had visible
numbers of astrocyte-like cells were discarded (typically dishes with >625 cells per well).
Those cultures without visible astrocyte-like cells (usually dishes with 625 and 312 cells per
well) were pooled and further expanded for 15 passages in the presence of CGM. The resulting
cell population of OL-1 cells was composed predominately of bipolar cells with a minority of
multipolar cells without visible traces of astrocyte-like or mature oligodendrocyte-like cells.
2.1.2. Management of the OL-1 cell line—Undifferentiated OL-1 cells were propagated
in CGM at 37 °C in a CO2 incubator. Once cells were grown to sub-confluence, they were
passaged. After CGM was aspirated and cells washed with papain buffer, cells were incubated
with papain (1–2 U/mL) at 37 °C. After 2 min, cool wash buffer (DMEM, 0.1% BSA, 20 mM
Hepes, 5 U/mL penicillin/streptomycin) was added and cells were detached from culture dishes
by trituration. After spinning at 1000 rpm at 4 °C for 7 min, the supernatant was removed. Cells
were re-suspended in 30 mL of CGM, seeded into 3 PDL-coated plates, and incubated at 37 °
C.
2.2. Characterization of the OL-1 oligodendrocyte precursor cell line
2.2.1. OL-1 cell morphology and glial gene expression—Undifferentiated OL-1 cells
are propagated in CGM. Withdrawal of CGM and addition of SFM promotes OL-1 cell
maturation and results in decreased proliferation. To characterize the morphology and glial
gene expression of both undifferentiated and differentiated OL-1 cells, as well as to define the
time course of OL-1 cell morphological changes during maturation, OL-1 cells were expanded
in CGM for 3 passages and plated into sterile PDL-coated 12-well tissue culture plates (Falcon)
at a concentration of 60,000 cells/well. Twelve-well plates were then cultured for 24 h in CGM
at 37 °C in a CO2 incubator to allow cells to attach and stabilize. CGM was then removed and
replaced with either: (1) fresh CGM or (2) SFM (10 μg/mL insulin). Plates were cultured for
48 h and collected at the following times: (1) CGM at time 0 h; (2) CGM and SFM at 24 h; (3)
CGM and SFM at 48 h. At the time of collection, quadruplicate OL-1 cell cultures were
photographed, promptly passaged, re-suspended in phosphate buffered saline (PBS), counted
with a hemocytometer, quickly frozen in liquid nitrogen, and stored at −80 °C until analysis.
Both CGM and SFM contain levels of insulin (10 μg/mL) that would be expected to maximally
activate both the insulin and IGF1-R, thus providing tonic insulin and IGF-I effects. Because,
insulin at a concentration of 10 μg/mL also stimulates the type I IGF receptor (IGF1-R), the
cell surface receptor that mediates IGF-I signaling, we used SFM that contained insulin at a
physiological concentration (5 ng/mL) in all experiments examining IGF-I actions. At this
concentration, insulin does not interact significantly with the IGF1-R. SFM containing 5 ng/
mL insulin is termed low insulin SFM hereafter.
To characterize the effects of IGF-I on OL-1 cell maturation and glial gene expression, OL-1
cells were expanded in CGM for three passages and plated into PDL-coated 12-well tissue
culture plates at a concentration of 60,000 cells/well in CGM and cultured for 24 h at 37 °C.
CGM was then removed and replaced with either: (1) low insulin SFM (5 ng/mL insulin) or
(2) low insulin SFM with 100 ng/mL IGF-I. Plates were cultured for 48 h and collected at the
following times: (1) CGM at time 0 h; (2) low insulin SFM and low insulin SFM with 100 ng/
mL IGF-I at 24 h; low insulin SFM and low insulin SFM with 100 ng/mL IGF-I at 48 h. At
the time of collection, quadruplicate OL-1 cell cultures were photographed, promptly passaged,
re-suspended in phosphate buffered saline (PBS), counted with a hemocytometer, quickly
frozen in liquid nitrogen, and stored at −80 °C until further analysis.
To quantify the effect of IGF-I on OL-1 cell maturation morphologically, the number of OL-1
cell processes per cell was evaluated. OL-1 cells were expanded in CGM and plated into PDL-
coated 12-well tissue culture plates at a concentration of 60,000 cells/well. Plates were then
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cultured for 24 h in CGM at 37 °C to allow cells to attach and stabilize. CGM was then removed
from all wells and replaced with either low insulin SFM or low insulin SFM with 100 ng/mL
IGF-I. Plates were cultured for 48 h and the number of OL-1 cell processes determined at 24
and 48 h. OL-1 cell process number was determined by randomly visualizing cells from each
treatment group and counting the number of cell processes that extended from each OL-1 cell
body. A total of 10 cells per treatment group were evaluated and mean number of processes
per cell determined. Comparisons between the IGF-I treated and SFM treated group were made
using a Student’s t-test.
2.2.2. RNA extraction, reverse transcription, and quantitative real-time PCR—
Total RNA was extracted from collected samples using Trizol reagent (Invitrogen, Carlsbad,
CA) per the manufacturer’s protocol and stored at −80 °C until further analysis. cDNA was
generated utilizing a 20 μL reverse transcription (RT) reaction with the following final
concentrations of reagents in the RT reaction mixture: 10 U/μL Superscript II RNAse H
Reverse Transcriptase (Invitrogen, Carlsbad, CA), 2 U/μL RNAsin (Promega, Madison, WI),
1 mM dNTP-Mix (Qiagen, Valencia, CA), 5 μM random decamers (UNC nucleic acid core
facility), 5 mM DTT (Invitrogen, Carlsbad, CA), and 1× first strand buffer (Invitrogen,
Carlsbad, CA). The RNA load for each RT reaction was normalized for cell number. Reactions
were carried out at 37 °C for 60 min followed by 3 min at 95 °C on a GeneAmp PCR System
2400 (Perkin Elmer, Boston, MA). RT reaction products were stored at −20 °C until further
analysis.
The relative expression of OL-1 cell markers was quantified using quantitative real-time PCR
(qRT-PCR). Gene transcripts were quantified using the LightCycler qRT-PCR system (Roche
Applied Science, Indianapolis, IN) and analyzed using LightCycler software version 3.5
(Roche Applied Science, Indianapolis, IN). Primer sequences (Table 1) were designed so that
qRT-PCR products crossed exon–exon splice junctions so as to eliminate the possibility of
amplifying genomic DNA. PLP primers were designed to amplify both PLP and DM-20 cDNA
transcript isoforms. When amplifying PLP cDNA a 616bp qRT-PCR product is generated, and
when amplifying DM-20, a 511bp qRT-PCR product is generated. qRT-PCR analysis using
these primers, therefore, yields the sum of both PLP and DM-20 expression. Twenty microliter
qRT-PCR reactions were carried out with the following final concentrations of reagents: 3 μL
cDNA, 1× QuantiTect SYBR Green Master Mix (Qiagen, Valencia, CA), 1 μM primer A, 1
μM primer B). After an initial denaturation step (95 °C for 20 min), amplification was
performed over 40–45 cycles of denaturation (94 °C for 30 s), annealing (55 °C for 60 s),
elongation (72 °C for 60 s), and fluorometric detection (78 °C for 5 s). To minimize variability,
reagents were prepared as master mixes, aliquoted into individual tubes, and cDNA added to
each reaction. Gene transcripts of 18S ribosomal RNA were quantified and used to normalize
the load of cDNA in each sample. Reaction specificity was monitored by performing a melting
curve analysis at the end of each reaction. Because, the melting curve of a PCR product is
dependent upon its GC content, sequence, and length, specific amplification products can be
distinguished from non-specific ones by examination of the melting curve (Dhar et al.,
2002;Ririe et al., 1997). In addition, all samples were analyzed by electrophoresis utilizing a
1.5% agarose gel to confirm that the actual sizes of qRT-PCR products were the same as their
predicted sizes. To further confirm specificity, qRT-PCR products were extracted from agarose
gels using a QIAquick gel extraction kit (Qiagen, Valencia, CA) and sequenced by the
University of North Carolina Automated DNA Sequencing Facility. Sequencing reactions were
performed using the chain terminator method utilizing the ABI PRISM BigDye Terminator
Cycle Sequencing Ready Reaction Kit with AmpliTaq DNA Polymerase, FS (Applied
Biosystems, Foster City, CA). DNA sequences were compared by BLAST analysis to the
online rat GenBank mRNA sequences (http://www.ncbi.nlm.nih.gov/) for each marker of
interest. The CT for each marker was normalized to 18S by subtracting the CT 18S from
CT marker. The effect of treatment (ΔCT) was calculated by subtracting the 18S-normalized
Lagarde et al. Page 5













CT at the beginning of the experiment (time 0) from the 18S-normalized ΔCT at the end of the
experiment (48 h). The expression of PLP relative to DM-20 was carried out in a semi-
quantitative fashion by the electrophoresis of PLP/DM-20 qRT-PCR products on a 1.5%
agarose gel and visualization with ethidium bromide staining.
2.2.3. Western blot analysis—OL-1 cells were collected at 0 and 48 h after withdrawal of
CGM and culture in SFM, washed with PBS, and lysed with a protein extract buffer (20 mM
Tris–HCl, pH 7.5, 1% NP-40, 137 mM NaCl, 1 mM CaCl2, 1 mM EDTA, and freshly added
0.5 mM PMSF and 2.5 mg/mL of each aprotinin, leupeptin and antipain). Total protein was
collected by centrifugation at 12,000 rpm for 5 min at 4 °C. Protein concentration was
determined using a BCA protein kit (Pierce, Rockford, IL) and bovine serum albumin as a
standard. Aliquots of total protein (10–30 μg) were separated on 12.5% polyacrylamide gels
and transferred onto PVDF nylon membranes (Amersham, Arlington Heights, IL). Membranes
were incubated with specific antibody. Antibody concentration used is as follows: 2′,3′-Cyclic
nucleotide 3′-phosphodiesterase (CNP) (1:300, Chemicon International, Temecula, CA),
Neurofilament (NF) (1:500, Chemicon), glial fibrillary acidic protein GFAP (1:2000,
Chemicon), β-actin (1:500, Sigma), Specific immunoreactivity was visualized using an ECL
kit (Amersham), according to the manufactures protocol.
2.2.4. Immunohistochemistry—To further characterize the nature of both undifferentiated
and differentiated OL-1 cells, immunohistochemical staining for the immature and mature
oligodendrocyte-specific cell surface markers, A2B5 and myelin basic MBP, respectively, was
carried out. OL-1 cells were expanded in CGM for three passages and plated into sterile PDL-
coated Lab-Tek chamber slides (Nalge Nunc, Rochester, NY) at a concentration of 20,000
cells/well. The chamber slides were then cultured for 24 h in CGM at 37 °C in a CO2 incubator
to allow cells to attach and stabilize. After the stabilization period, one-third of the chamber
slides were collected for analysis. The remaining slides were cultured at 37 °C in SFM to
promote maturation and then collected at 24 and 48 h for analysis. OL-1 cells were fixed with
4% paraformaldehyde for 10 min at 25 °C followed by washing 3× with PBS. Cells were then
treated with 3% H2O2 for 3 min at 25 °C and washed with PBS 3× to quench endogenous
peroxidase activity. Primary antibody was prepared at a concentration of 1:25 (mouse anti-
A2B5 IgM; Chemicon, Temecula, CA) or 1:200 (rabbit anti-MBP IgG; Chemicon, Temecula,
CA) in PBS/0.1% Triton X-100 (TX-100) and applied for 2 h at 25 °C. Cells were washed 3×
with PBS and then secondary antibody (rhodamine-conjugated goat anti-mouse IgM or
fluorescein-conjugated goat anti-rabbit IgG; Jackson, ImmunoResearch Laboratories, West
Grove, PA) was prepared at a concentration of 1:200 in PBS/0.1% TX-100 and applied for 1
h at 25 °C followed by washing with PBS 3×. Images were visualized with an Olympus BX-60
fluorescent microscope and images acquired using the Spot Jr. Digital Acquisition System
(Diagnostic Instruments, Sterling Heights, MI).
2.2.5. Cell number—To determine the effect of IGF-I on OL-1 cell number, OL-1 cells were
propagated in CGM and passaged to sterile PDL-coated 12-well tissue culture plates. Cells
were cultured for 3 h in CGM at 37 °C in a CO2 incubator to allow cells to attach and stabilize.
CGM was removed and OL-1 cells were cultured for 24 h at 37 °C in low insulin SFM or low
insulin SFM with 100 ng/mL IGF-I. Cell number was determined at 3, 6, 12, 18, and 24 h by
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphyneltetrazolium bromide) assay (Denizot and
Lang, 1986) according to the manufacturers protocol (Sigma). Briefly, 0.5 mg/mL MTT was
added to OL-1 cell cultures for 3 h prior to the end of each culture period followed by
withdrawal of culture media and addition of 0.1N HCl in anhydrous isopropanol (MTT
solvent). Optical absorbance was measured at 570 and 630 nm using a Beckman
spectrophotometer (model DU-65). The difference between OD 570 and OD 630 (Δ570–630)
was determined. The Δ570–630 values closely correlated with cell number.
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2.2.6. Caspase inhibitor studies—To determine if the IGF-I-induced increase in OL-1
cell number is mediated through inhibition of apoptosis, OL-1 cells were propagated in CGM
and passed to sterile PDL-coated 12-well tissue culture plates. Cells were then cultured for 3
h in CGM at 37 °C in a CO2 incubator to allow cells to attach and stabilize. CGM was removed
and OL-1 cells were cultured for 24 h in low insulin SFM, low insulin SFM with caspase
inhibitors Z-VAD-FMK or Z-DEVD-FMK (inhibitors of caspases 3, 6, 7, 8, 10 and 1, 3, 4,
respectively), low insulin SFM with 100 ng/mL IGF-I, or low insulin SFM with both 100 ng/
mL IGF-I and caspase inhibitor (Z-VAD-FMK or Z-DEVD-FMK). Cell number was
determined at 24 h by MTT assay.
2.2.7. Proliferation studies—To determine if the IGF-I-induced increase in OL-1 cell
number is mediated through increased proliferation, OL-1 cells were propagated in CGM and
passaged to sterile PDL-coated 12-well tissue culture plates. Cells were then cultured for 3 h
in CGM at 37 °C in a CO2 incubator to allow cells to attach and stabilize. CGM was removed
and OL-1 cells were cultured for 3, 6, 12, 18 and 24 h at 37 °C in CGM, low insulin SFM, or
low insulin SFM with 100 ng/mL IGF-I. Cell proliferation was determined by BrdU labeling.
Briefly, 5 μg/mL BrdU was added to OL-1 cell cultures for 3 h prior to the end of each culture
period. This was followed by fixation in 4% paraformaldehyde, treatment with 3% H2O2 and
2N HCl, and blocking with 5% milk protein in PBS 0.1% TX-100. BrdU labeled cells were
identified with monoclonal antibody against BrdU (1:200; Boehringer Mannheim,
Indianapolis, IN). Antibody-antigen complexes were detected using the EnVision + Peroxidase
system (Dako North America, Carpinteria, CA). Labeled cells were visualized under a
microscope and 200 cells counted to determine the BrdU labeling index expressed as a
percentage of total cells.
2.2.8. Statistical analyses—Comparisons between treatment groups were made using a
Student’s t-test. Statistical analyses were performed using STATA statistical analysis software
(StatCorp, College Station, TX).
3. Results
3.1. OL-1 cells exhibit morphologic and immunologic changes consistent with developing
oligodendrocytes
OL-1 cells, when propagated at 37 °C in CGM, proliferate and display immature morphology
consistent with that of oligodendrocyte precursors (Fig. 1, panels A and B). Cells are
predominantly bipolar and tri-polar, display a small ovoid cell body, and their processes display
relatively few branches. Following withdrawal of CGM, culture of OL-1 cells in SFM promotes
maturation of the cells over a 48 h period (Fig. 1, panels C and D). During the maturation
process, the cell bodies shifted from an ovoid to a more rounded appearance and additional
processes formed with an increased number of branches. The mature cells are stellate and
display multiple processes that are highly branched. When cultured in sufficient density they
have a morphology, including sheet-like processes, that is consistent with that of mature
oligodendrocytes generated using primary cell culture techniques (Fig. 2).
To further characterize the OL-1 cell expression of oligodendrocyte-specific developmental
markers, OL-1 cells propagated in CGM (immature) or SFM for 24 h (mature) were
immunostained for A2B5 (an oligodendrocyte precursor marker) and MBP (a mature
oligodendrocyte marker). OL-1 cells cultured in CGM displayed strong A2B5
immunoreactivity with little to no immunoreactivity to MBP, whereas OL-1 cells cultured in
SFM for 24 h displayed strong MBP immunoreactivity with little to no immunoreactivity to
A2B5 (Fig. 3).
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3.2. Proteolipid protein (PLP/DM-20), NG2 proteoglycan (NG2) mRNA and 2′,3′-cyclic
nucleotide 3′-phosphodiesterase (CNP) protein are expressed in a developmentally specific
fashion during OL-1 cell maturation
To investigate whether OL-1 cells express oligodendrocyte-specific markers as they undergo
morphological development, we utilized qRT-PCR in conjunction with RT to examine the
expression of NG2 (an oligodendrocyte precursor cell specific marker), PLP/DM-20 (a mature
oligodendrocyte cell specific marker), and GFAP (an astrocyte cell specific marker) during
OL-1 cell propagation and maturation. OL-1 cells were propagated in CGM or SFM for 48 h.
Expression of NG2, PLP/DM-20, and GFAP mRNA were determined at the beginning and
end of the experiment, and results are reported as the change in CT (ΔCT) from the beginning
of the experiment. OL-1 cells cultured in SFM showed a significant decrease in NG2 mRNA
expression ( p < 0.05), a significant increase in PLP/DM-20 mRNA expression ( p < 0.05), and
a significant decrease in GFAP mRNA expression ( p < 0.05; Fig. 4). OL-1 cells propagated
in CGM did not exhibit a significant change in NG2 and PLP/DM-20 mRNA expression and
exhibited a significant increase in GFAP mRNA expression ( p < 0.05; Fig. 4). To confirm the
specificity of the reactions, qRT-PCR products were gel-purified and sequenced. Comparison
of the NG2, PLP/DM-20, and GFAP qRT-PCR product DNA sequences to the online rat
GenBank mRNA sequences confirmed their match with the respective genes of interest (data
not shown).
In addition, Western blot analysis was carried out to evaluate the expression of
oligodendrocyte-specific proteins during OL-1 cell maturation. CNP (a mature
oligodendrocyte cell specific protein), NF (a neural cell specific protein), and GFAP (an
astrocyte cell specific protein) protein expression were determined at 0 and 48 h following
withdrawal of CGM and culture in SFM. OL-1 cells exhibited increased CNP protein
expression and decreased GFAP protein expression during their maturation over a 48 h period
(Fig. 5). NF was not significantly expressed by OL-1 cells.
3.3. Immature OL-1 cells express both PLP and DM-20 equally, whereas, mature OL-1 cells
express predominately PLP
To determine the relative expression of PLP compared to DM-20 in immature and mature OL-1
cells, PLP/DM-20 qRT-PCR products (generated from the analysis of immature and mature
OL-1 cells) were analyzed by agarose gel electrophoresis. Immature OL-1 cells expressed
similar quantities of both PLP and DM-20. In contrast, mature OL-1 cells expressed a greater
proportion of PLP compared to immature OL-1 cells (Fig. 6).
3.4. IGF-I promotes OL-1 cell maturation and PLP/DM-20 expression
To evaluate the effect of IGF-I on OL-1 cellular maturation, the number of OL-1 processes
was determined 24 and 48 h following IGF-I treatment (Fig. 7 shows these morphological
changes). OL-1 cells treated with IGF-I displayed a significantly greater number cell processes
per cell at 24 and 48 h (8.7 ± 1.16 and 8.8 ± 1.32, respectively; p < 0.05) compared to OL-1
cells treated with SFM alone (6.0 ± 1.70 and 5.9 ± 0.74).
Next, to investigate the effect of IGF-I on the expression of NG2, PLP/DM-20, and GFAP,
OL-1 cells were cultured in low insulin SFM or low insulin SFM with 100 ng/mL IGF-I for
48 h and the expression of NG2, PLP/DM-20, and GFAP determined at the beginning and end
of the experiment using qRT-PCR in conjunction with RT. The effect of treatment was
expressed as the change in CT (ΔCT) from the beginning of the experiment. OL-1 cells cultured
in low insulin SFM with IGF-I showed significantly greater PLP/DM-20 mRNA expression
than OL-1 cells propagated in low insulin SFM alone ( p < 0.05; Fig. 8). Although there was
a trend toward less NG2 and GFAP mRNA expression in OL-1 cells treated with IGF-I
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compared to cells cultured in low insulin SFM alone, these differences were not significant
(Fig. 8).
3.5. IGF-I treatment increases cell number during OL-1 cellular maturation primarily by
inhibiting apoptosis
To determine the effect on IGF-I on cell number, OL-1 cells were cultured for 24 h at 37 °C
in low insulin SFM or low insulin SFM with 100 ng/mL IGF-I and cell number determined by
MTT assay at 3, 6, 12, 18, and 24 h. OL-1 cell number was significantly greater during treatment
with IGF-I at 6, 12, 18, and 24 h compared to treatment with low insulin SFM. Furthermore,
IGF-I treatment significantly increased OL-1 cell number by 12 h compared to the beginning
of the experiment ( p < 0.05), and this effect persisted at 18 ( p < 0.05) and 24 h ( p < 0.05;
Fig. 9). In contrast, when cultured in low insulin SFM, OL-1 cell number was significantly
decreased compared to the beginning of the experiment at 6 h ( p < 0.05), and this effect also
persisted at 12 ( p < 0.05), 18 ( p < 0.05), and 24 h ( p < 0.05; Fig. 9).
To investigate the mechanism by which IGF-I increases cell number, we evaluated the effect
of the caspase inhibitors Z-DEVD-FMK and Z-VAD-FMK (inhibitors of caspases 3, 6, 7, 8,
10 and 1, 3, 4, respectively) on OL-1 cell number. OL-1 cells were cultured for 24 h in low
insulin SFM alone, low insulin SFM with inhibitors, low insulin SFM with 100 ng/mL IGF-I
without inhibitor, and low insulin SFM with 100 ng/mL IGF-I and inhibitors. Cell number was
determined at 24 h by MTT assay. Treatment with Z-DEVD-FMK, increased OL-1 cell number
significantly ( p < 0.05), compared to the beginning of the experiment and there was a trend
toward further increases in cell number with increasing concentrations of inhibitor (Fig. 10,
panel A). There was also a significant increase in OL-1 cell number compared to the beginning
of the experiment with Z-VAD-FMK treatment ( p < 0.05); however, this effect was lost at
inhibitor concentrations greater than 20 μM (Fig. 10, panel B). Concurrent treatment with
caspase inhibitors and IGF-I did not increase OL-1 cell number to the extent of IGF-I treatment
alone (Fig. 10, panels A and B).
To investigate whether proliferation plays a significant role in IGF-I-stimulated increases in
cell number, BrdU incorporation into OL-1 cells was determined during IGF-I exposure. OL-1
cells were cultured for 24 h at 37 °C in CGM, low insulin SFM, or low insulin SFM with 100
ng/mL IGF-I, and BrdU labeling determined at 3, 6, 12, 18, and 24 h. BrdU positive cells were
expressed as a percentage of total cells. Propagation of OL-1 cells in CGM resulted in sustained
BrdU labeling ranging from 44 to 56%. IGF-I exposure increased the percentage of BrdU
labeled OL-1 cells compared to low insulin SFM treatment at 3, 6, 18, and 24 h (Fig. 11). IGF-
I treatment, however, resulted in a progressive decline in the percentage of BrdU labeled cells
from 47% at the beginning of the experiment to 14% at 24 h compared to CGM (Fig. 11).
4. Discussion
A non-immortalized oligodendrocyte precursor cell line, OL-1, is described that shares the
characteristics of primarily cultured oligodendrocyte progenitors and provides a model of in
vivo oligodendrocyte development. Study of OL-1 cells facilitates investigation into
oligodendrocyte lineage signaling mechanisms. Only one such cell line, CG-4, has been
reported, and thus OL-1 cells offer an alternative culture model for the study of either OPCs,
mature oligodendrocytes, or OPCs undergoing differentiation. Our findings that IGF-I actions
on OL-1 cells parallels its actions on OPCs in vivo and in vitro, namely promotion of
differentiation and survival, strongly supports the value of this cell line as an investigational
model.
OL-1 cells can be propagated in culture to obtain large numbers of cells and can be
cryopreserved for future use. OL-1 cells have morphology consistent with immature
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oligodendrocytes and withdrawal of CGM promotes their development into mature
oligodendrocytes. As OL-1 cells mature, their number decreases and there is a shift from the
expression of immature cell markers (A2B5 and NG2) to mature cell markers (MBP and PLP/
DM-20). Furthermore, immature OL-1 cells express PLP and DM-20, whereas, mature OL-1
cells predominantly express PLP. With exposure to IGF-I, OL-1 cells develop an increased
number of processes, increased PLP/DM-20 expression, and exhibit increased cell survival.
Concurrent treatment of OL-1 cells with IGF-I and caspase inhibitors Z-DEVD-FMK and Z-
VAD-FMK (inhibitors of caspases 3, 6, 7, 8, 10 and 1, 3, 4, respectively) and BrdU studies
indicate that the IGF-I-stimulated increases in cell number are mediated primarily through
increased survival. Thus, OL-1 cells exhibit morphologic progression and changes in cell
markers consistent with developing oligodendrocytes, and OL-1 cells exposed to IGF-I exhibit
responses consistent with developing oligodendrocytes in vivo (de Vellis, 1990; Richardson,
2001).
The OL-1 line was developed by first generating mixed glial cultures from P2 rat brains
according to the method of McCarthy and de Vellis (1980) followed by separation and
expansion of oligodendrocyte precursors in CGM. The method is similar to that used by Louis
et al. (1992) during the generation of the CG-4 cell line (an oligodendrocyte precursor cell line
similar to OL-1) with a few differences. First, we used fetal calf serum during the initial
generation of the mixed glial cultures in contrast to the calf serum used by Louis et al.
(1992). This difference in the serum used may explain why most of the lines generated by Louis
et al. prior to CG-4 died after a limited number of passages, because fetal calf serum likely
contains greater quantities of trophic factors and/or distinct factors that support and/or facilitate
OPCs propagation. Second, by using serial dilutions to isolate and subsequently expand OPCs,
OL-1 cells are derived from a pool of precursors rather than a single cell. We suspect that this
reduced the possibility of the selection of cells with aberrant characteristics.
When OL-1 cells are propagated in CGM they exhibit morphology consistent with immature
oligodendrocytes (bipolar shapes and ovoid cell body). A2B5 immunoreactivity is strong and
MBP immunoreactivity is absent. Under these conditions, OL-1 cells fail to mature and do not
express markers of mature oligodendrocyte function. Expansion of OL-1 cells in CGM, thus
provides a means of generating large numbers of oligodendrocyte precursors for study. After
withdrawal of CGM, OL-1 cells develop rounded cell bodies and dramatically increased
numbers of cell processes with complex branching patterns. During this process they exhibit
decreased A2B5 immunoreactivity and NG2 mRNA expression, increased MBP
immunoreactivity, PLP/DM-20 mRNA expression, and CNP protein expression, and their
number decreases. Immature OL-1 cells express DM-20 and PLP mRNA in roughly equal
proportions, while mature OL-1 cells express predominately PLP mRNA. These findings are
consistent with the behavior of developing oligodendrocytes both in vivo and in vitro (de Vellis,
1990; Richardson, 2001) and the O2A-like oligodendrocyte precursor cell line CG-4 developed
by Louis et al. (1992). OL-1 cells propagated in CGM under the conditions in our experiments
resulted in significant increases in GFAP expression. However, the cells propagated in CGM
were significantly overgrown at the end of the experiment (48 h; data not shown). During
propagation of the OL-1 cell line in CGM, therefore, great care was taken to not allow the cells
to overgrow.
The maturation of OL-1 cells into mature oligodendrocytes over a 48 h period following
withdrawal of CGM and culture in SFM is consistent with the maturation time of other OPC
culture systems reported in the literature including CG-4 cells (Louis et al., 1992) and O2A
cells (Raff et al., 1983). Although significant maturation occurs within the first 24 h of culture
in SFM, OL-1 cells mature substantially further when culture is continued to 48 h and even
further when continued to 72 h. More important than their time to maturation are the findings
that: (1) OL-1 cell maturation is predictably and tightly controlled by CGM withdrawal and
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the addition SFM and (2) the rate and homogeneity of phenotypic maturation is consistent
among multiple experiments. To evaluate the utility of the OL-1 cell line as a model for the
study of the IGF-I actions during oligodendrocyte development, we exposed OL-1 cells to IGF-
I during their maturation into oligodendrocytes. Exposure to IGF-I promoted increased
numbers of cell processes, increased PLP/DM-20 expression, and increased OL-1 cell number.
This is consistent with IGF-I actions on developing oligodendrocytes and myelin in vivo (Beck
et al., 1995; Carson et al., 1993; D’Ercole et al., 1994; Murphy et al., 1993; Ye et al., 1995;
Ye et al., 2002). Exposure of OL-1 cells to caspase inhibitors also produced increases in OL-1
cell number, but to a lesser degree than IGF-I. Concurrent treatment with caspase inhibitors
and IGF-I produced increases in OL-1 cell number equivalent to that observed with IGF-I.
These data indicate that the effect of IGF-I on OL-1 cell number is at least in part mediated
through inhibition of apoptosis. The observation that caspase inhibitor treatment did not
completely replicate the effect of IGF-I could be explained by: (1) incomplete inhibition of the
caspase activity by Z-DEVD-FMK and Z-VAD-FMK, (2) the actions of caspases other than
those inhibited by Z-DEVD-FMK and Z-VAD-FMK on IGF-I anti-apoptotic action, (3)
increased proliferation, and/or (4) other mechanisms involved in IGF-I mediated cell survival.
To determine whether IGF-I-stimulated increases in cell number are mediated by stimulation
of cell proliferation, we assessed BrdU incorporation in OL-1 cells. As expected, OL-1 cells
propagated in CGM exhibited sustained and high levels of BrdU incorporation, while OL-1
cells propagated in SFM displayed a progressive decline in BrdU incorporation. Although
exposure to IGF-I resulted in slightly greater BrdU incorporation, progressive decreases in
BrdU incorporation similar to cells cultured in SFM were observed. This suggests that while
the IGF-I stimulated increases in OL-1 cell number may in part be explained by increased
proliferation, IGF-I effects are predominantly mediated through increases in cell survival.
BrdU uptake, however, has been reported to occur as part of the apoptotic process (Kuan et
al., 2004), and thus, IGF-I’s sole action on OL-1 cell number may be anti-apoptotic. These data
are consistent with previous in vitro studies (Barres et al.,1993; Vemuri and McMorris,
1996) and collectively support the notion that IGF-I stimulated increases in cell number during
OL-1 cell maturation are mediated by inhibition of apoptosis.
In conclusion, we have established a non-immortalized oligodendrocyte precursor cell line that
develops into mature oligodendrocytes in vitro following withdrawal of CGM and culture in
SFM. The behavior of OL-1 cells during maturation is consistent with oligodendrocyte
precursors and developing oligodendrocytes, as well as with the CG-4 cell line. With exposure
to IGF-I, OL-1 cells develop increased number of cell processes, increased PLP/DM-20
expression, and enhanced cell survival consistent with in vivo IGF-I actions on developing
oligodendrocytes and myelin. OL-1 cells may also be easily propagated in vitro to provide the
large numbers of cells needed for experiments. Cells may be cryopreserved and stored for use
in future experiments. Thus, the OL-1 cell line provides an excellent alternative cell culture
model for the study of oligodendrocyte development.
Acknowledgements
This work was supported by NIH grants NS038891 and NS048868 (to AJD).
References
Barres BA, et al. Multiple extracellular signals are required for long-term oligodendrocyte survival.
Development 1993;118(1):283–295. [PubMed: 8375338]
Beck KD, et al. Igf1 gene disruption results in reduced brain size, CNS hypomyelination, and loss of
hippocampal granule and striatal parvalbumin-containing neurons. Neuron 1995;14(4):717–730.
[PubMed: 7718235]
Lagarde et al. Page 11













Bogler O, et al. Cooperation between two growth factors promotes extended self-renewal and inhibits
differentiation of oligodendrocyte-type-2 astrocyte (O-2A) progenitor cells. Proc Natl Acad Sci USA
1990;87(16):6368–6372. [PubMed: 2201028]
Calver AR, et al. Oligodendrocyte population dynamics and the role of PDGF in vivo. Neuron 1998;20
(5):869–882. [PubMed: 9620692]
Carson MJ, et al. Insulin-like growth factor I increases brain growth and central nervous system
myelination in transgenic mice. Neuron 1993;10(4):729–740. [PubMed: 8386530]
D’Ercole AJ, et al. Brain growth retardation due to the expression of human insulin like growth factor
binding protein-1 in transgenic mice: an in vivo model for the analysis of igf function in the brain.
Brain Res Dev Brain Res 1994;82(12):213–222.
de Vellis J. Developmental and hormonal regulation of gene expression in oligodendrocytes. Ann NY
Acad Sci 1990;605:81–89. [PubMed: 2268122]
Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival Modifications to the tetrazolium
dye procedure giving improved sensitivity and reliability. J Immunol Meth 1986;89(2):271–277.
Dhar AK, Roux MM, Klimpel KR. Quantitative assay for measuring the Taura syndrome virus and yellow
head virus load in shrimp by real-time RT-PCR using SYBR Green chemistry. J Virol Meth 2002;104
(1):69–82.
Fruttiger M, et al. Defective oligodendrocyte development and severe hypomyelination in PDGF-A
knockout mice. Development 1999;126(3):457–467. [PubMed: 9876175]
Gard AL, Pfeiffer SE. Glial cell mitogens bFGF and PDGF differentially regulate development of O4 +
GalC-oligodendrocyte progenitors. Dev Biol 1993;159(2):618–630. [PubMed: 8405684]
Hall A, Giese NA, Richardson WD. Spinal cord oligodendrocytes develop from ventrally derived
progenitor cells that express PDGF alpha-receptors. Development 1996;122(12):4085–4094.
[PubMed: 9012528]
Jung M, et al. Lines of murine oligodendroglial precursor cells immortalized by an activated neu tyrosine
kinase show distinct degrees of interaction with axons in vitro and in vivo. Eur J Neurosci 1995;7
(6):1245–1265. [PubMed: 7582098]
Kuan CY, et al. Hypoxia-ischemia induces DNA synthesis without cell proliferation in dying neurons in
adult rodent brain. J Neurosci 2004;24(47):10763–10772. [PubMed: 15564594]
Lee JC, Mayer-Proschel M, Rao MS. Gliogenesis in the central nervous system. Glia 2000;30(2):105–
121. [PubMed: 10719353]
Louis JC, et al. CG-4, a new bipotential glial cell line from rat brain, is capable of differentiating in vitro
into either mature oligodendrocytes or type-2 astrocytes. J Neurosci Res 1992;31(1):193–204.
[PubMed: 1613821]
Matsushita T, et al. A novel oligodendrocyte cell line OLP6 shows the successive stages of
oligodendrocyte development: late progenitor, immature and mature stages. Neuroscience 2005;136
(1):115–121. [PubMed: 16181743]
McCarthy KD, de Vellis J. Preparation of separate astroglial and oligodendroglial cell cultures from rat
cerebral tissue. J Cell Biol 1980;85(3):890–902. [PubMed: 6248568]
McKinnon RD, et al. FGF modulates the PDGF-driven pathway of oligodendrocyte development. Neuron
1990;5(5):603–614. [PubMed: 2171589]
McMorris FA, Dubois-Dalcq M. Insulin-like growth factor I promotes cell proliferation and
oligodendroglial commitment in rat glial progenitor cells developing in vitro. J Neurosci Res 1988;21
(2–4):199–209. [PubMed: 3216421]
McMorris FA, et al. Insulin-like growth factor I/somatomedin C: a potent inducer of oligodendrocyte
development. Proc Natl Acad Sci USA 1986;83(3):822–826. [PubMed: 3511475]
Mozell RL, McMorris FA. Insulin-like growth factor I stimulates oligodendrocyte development and
myelination in rat brain aggregate cultures. J Neurosci Res 1991;30(2):382–390. [PubMed: 1665869]
Murphy LJ, Barron D, Seneviratne C. Hormonal regulation of insulin-like growth factor binding protein-1
expression and the development of transgenic mouse models to study IGFBP-1 function. Adv Exp
Med Biol 1993;343:279–291. [PubMed: 7514341]
Nishiyama A, et al. Co-localization of NG2 proteoglycan and PDGF alpha-receptor on O2A progenitor
cells in the developing rat brain. J Neurosci Res 1996;43(3):299–314. [PubMed: 8714519]
Lagarde et al. Page 12













Noble M, et al. Platelet-derived growth factor promotes division and motility and inhibits premature
differentiation of the oligodendrocyte/type-2 astrocyte progenitor cell. Nature 1988;333(6173):560–
562. [PubMed: 3287176]
Raff MC, et al. Platelet-derived growth factor from astrocytes drives the clock that times oligodendrocyte
development in culture. Nature 1988;333(6173):562–565. [PubMed: 3287177]
Raff MC, Miller RH, Noble M. A glial progenitor cell that develops in vitro into an astrocyte or an
oligodendrocyte depending on culture medium. Nature 1983;303(5916):390–396. [PubMed:
6304520]
Rao MS, Noble M, Mayer-Proschel M. A tripotential glial precursor cell is present in the developing
spinal cord. Proc Natl Acad Sci USA 1998;95(7):3996–4001. [PubMed: 9520481]
Richardson, WD. Oligodendrocyte development. In: Jessen, KR.; Richardson, WD., editors. Glial Cell
Development. 2. Oxford University Press; 2001.
Richardson WD, et al. A role for platelet-derived growth factor in normal gliogenesis in the central
nervous system. Cell 1988;53(2):309–319. [PubMed: 2834067]
Richter-Landsberg C, Heinrich M. OLN-93: a new permanent oligodendroglia cell line derived from
primary rat brain glial cultures. J Neurosci Res 1996;45(2):161–173. [PubMed: 8843033]
Ririe KM, Rasmussen RP, Wittwer CT. Product differentiation by analysis of DNA melting curves during
the polymerase chain reaction. Anal Biochem 1997;245(2):154–160. [PubMed: 9056205]
Vemuri GS, McMorris FA. Oligodendrocytes and their precursors require phosphatidylinositol 3-kinase
signaling for survival. Development 1996;122(8):2529–2537. [PubMed: 8756297]
Verity AN, et al. Expression of myelin protein genes and other myelin components in an oligodendrocytic
cell line conditionally immortalized with a temperature-sensitive retrovirus. J Neurochem 1993;60
(2):577–587. [PubMed: 7678286]
Ye P, Carson J, D’Ercole AJ. In vivo actions of insulin-like growth factor-I (IGF-I) on brain myelination:
studies of IGF-I and IGF binding protein-1 (IGFBP-1) transgenic mice. J Neurosci 1995;15(11):
7344–7356. [PubMed: 7472488]
Ye P, D’Ercole AJ. Insulin-like growth factor I protects oligodendrocytes from tumor necrosis factor-
alpha-induced injury. Endocrinology 1999;140(7):3063–3072. [PubMed: 10385398]
Ye P, et al. Myelination is altered in insulin-like growth factor-I null mutant mice. J Neurosci 2002;22
(14):6041–6051. [PubMed: 12122065]
Lagarde et al. Page 13














Representative photomicrographs of OL-1 cells following withdrawal of conditioned growth
media. (Panel A) OL-1 oligodendrocyte precursor cells (OPCs) after propagation in
conditioned growth media (CGM) display immature features, including ovoid cell body and
bipolar-tripolar shapes; (Panel B) OL-1 cells grown in CGM for 24 h display increased cell
density and retention of immature morphology; (Panels C and D) OL-1 cells grown in SFM
for 24 and 48 h, respectively, display a progression to mature oligodendrocyte morphology,
including round cell body and multi-polar appearance.
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MBP immunohistochemistry demonstrating sheet-like appearance of mature OL-1 cells. OL-1
cells cultured for 48 h in SFM showing mature multipolar cells that are strongly MBP positive
and exhibit a sheet-like appearance.
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A2B5 and MBP immunoreactivity of immature and mature OL-1 cells. (Panel A) OL-1 cells
cultured in CGM showing immature bipolar cells that strongly immunostain with antibody to
A2B5; (Panel B) OL-1 cells cultured for 24 h in SFM did not exhibit A2B5 immunostaining;
(Panel C) OL-1 cells cultured in CGM were MBP negative; (Panel D) OL-1 cells cultured for
24 h in SFM showing more mature multipolar cells that are strongly MBP positive.
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Relative expression of oligodendrocyte lineage cell specific markers in OL-1 cells. Following
withdrawal of CGM and culture in SFM for 48 h, expression of NG2 (oligodendrocyte
precursor cell specific marker), PLP/DM-20 (mature oligodendrocyte cell specific marker),
and GFAP (astrocyte cell specific marker) were determined by RT followed by qRT-PCR.
Relative expression is reported as the mean change in cycle number (n = 3) at 48 h from the
beginning of the experiment (ΔCT). NG2 expression was significantly decreased, PLP/DM-20
expression significantly increased, and GFAP expression significantly decreased when OL-1
cells were propagated in SFM (*p < 0.05). OL-1 cells propagated in CGM displayed no
significant change in NG2 and PLP/DM-20 expression and a significant increase in GFAP
expression (*p < 0.05).
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Expression of oligodendrocyte specific proteins during OL-1 cell maturation. Western blot
analysis evaluating the expression of CNP, NF, and GFAP in OL-1 cells at 0 and 48 h following
withdrawal of CGM and addition of SFM. CNP protein expression is increased and GFAP
protein expression is decreased during OL-1 cell maturation. NF is not significantly expressed
by OL-1 cells.
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Representative gel showing PLP and DM-20 expression in immature and mature OL-1 cells.
The left lane labeled CGM shows PLP/DM-20 PCR products from immature OL-1 cells
generated by propagation in CGM, while the right lane labeled SFM shows PLP/DM-20 PCR
products from mature OL-1 cells generated by culture in SFM. Note predominance of PLP
mRNA expression in mature OL-1 cells, compared to immature OL-1 cells.
Lagarde et al. Page 19














Representative photomicrographs of OL-1 cells following IGF-I treatment. (Panels A and B)
OL-1 cells grown 24 and 48 h, respectively, in low insulin SFM without IGF-I displaying
sequence of progression to mature oligodendrocyte morphology; (Panels C and D) OL-1 cells
grown 24 and 48 h, respectively, in low insulin serum free media with 100 ng/mL IGF-I. Note
that with IGF-I there is an increase in cell number and cells display an increase in the number
of cell processes.
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Relative expression of oligodendrocyte lineage cell specific markers in OL-1 cells during IGF-
I treatment. Following withdrawal of CGM and culture in low insulin SFM with 100 ng/mL
IGF-I for 48 h, expression of NG2 (oligodendrocyte precursor cell specific marker), PLP/
DM-20 (mature oligo-dendrocyte cell specific marker), and GFAP (astrocyte cell specific
marker) were determined by RT followed by qRT-PCR. Relative expression is expressed as
the mean change in cycle number (n = 3) at 48 h from the beginning of the experiment
(ΔCT). OL-1 cell PLP/DM-20 expression was significantly greater with IGF-I treatment (IGF)
compared to OL-1 cells propagated in low insulin SFM (*p < 0.05). There was no significant
change in NG2 and GFAP expression with IGF-I treatment compared to culture in low insulin
SFM.
Lagarde et al. Page 21














OL-1 cell number following withdrawal of conditioned growth media (CGM) and treatment
with IGF-I. Following withdrawal of CGM, OL-1 cells were treated with either low insulin
SFM or low insulin SFM with 100 ng/mL IGF-I for 24 h. Cell numbers are expressed as the
mean percentage (n = 8) of the 3 h low insulin (no IGF-I) SFM control. OL-1 cell number was
significantly greater with IGF-I treatment at 6, 12, 18, and 24 h compared to treatment with
low insulin SFM (*p < 0.05). IGF-I treatment also increased OL-1 cell number compared to
the beginning of the experiment 12, 18, and 24 h (*p < 0.05). When treated with low insulin
SFM, OL-1 cell number was significantly lower than the beginning of the experiment at 6, 12,
18, and 24 h (*p < 0.05).
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Ol-1 cell number following treatment with IGF-I and caspase inhibitors. (Panel A) OL-1 cells
treated with low insulin SFM, low insulin SFM with 100 ng/mL IGF-I with and without the
caspase inhibitor Z-DEVD-FMK, and with low insulin SFM with increasing concentrations of
caspase inhibitor. Z-DEVD-FMK inhibits caspases 3, 6, 7, 8, and 10. (Panel B) OL-1 cells
were treated with low insulin SFM, low insulin SFM with 100 ng/mL IGF-I with and without
the caspase inhibitor Z-VAD-FMK, and with low insulin SFM with increasing concentrations
of caspase inhibitor. Z-VAD-FMK inhibits caspases 1, 3, and 4. OL-1 cell number is expressed
as the mean percentage (n = 3) of the untreated control. OL-1 cell number was significantly
increased from control following IGF-I treatment (*p < 0.05). Treatment with caspase
inhibitors also increased OL-1 cell number (*p < 0.05) but to a lesser degree than IGF-I
treatment. Combined treatment with caspase inhibitors and IGF-I increased OL-1 cell number
(*p < 0.05) comparable to that of IGF-I treatment.
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BrdU labeled OL-1 cell number following IGF-I exposure. OL-1 cells were exposed to
conditioned growth media, low insulin SFM, or low insulin SFM with 100 ng/mL IGF-I for a
24 h period. BrdU was added to cultures for a 3 h period prior to cell harvest at 3, 6, 12, 18,
and 24 h. BrdU labeled and total OL-1 cell numbers were determined at 3, 6, 12, 18, and 24 h.
BrdU positive cells are expressed as a mean percentage (n = 2) of total cells and error bars
represent each of two duplicates. OL-1 cells propagated in CGM exhibited sustained levels of
BrdU labeling ranging from 44 to 56%. During IGF-I treatment, although BrdU labeling was
slightly increased compared to SFM, there was a progressive reduction in BrdU labeling from
47% at the beginning of the experiment to 14% at 24 h.
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Table 1
Primer sequences for OL-1 cell markers
Marker Nucleotide sequence (5′ → 3′) Orientation Size (bp)
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